[go: up one dir, main page]

MX2016010083A - Composicion farmaceutica para administracion topica. - Google Patents

Composicion farmaceutica para administracion topica.

Info

Publication number
MX2016010083A
MX2016010083A MX2016010083A MX2016010083A MX2016010083A MX 2016010083 A MX2016010083 A MX 2016010083A MX 2016010083 A MX2016010083 A MX 2016010083A MX 2016010083 A MX2016010083 A MX 2016010083A MX 2016010083 A MX2016010083 A MX 2016010083A
Authority
MX
Mexico
Prior art keywords
topical administration
pharmaceutical composition
sulfonyl
ethyl
compound
Prior art date
Application number
MX2016010083A
Other languages
English (en)
Other versions
MX381651B (es
Inventor
Leung LIU Wai
Purkins Lynn
Yeadon Michael
Original Assignee
Ziarco Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ziarco Pharma Ltd filed Critical Ziarco Pharma Ltd
Publication of MX2016010083A publication Critical patent/MX2016010083A/es
Publication of MX381651B publication Critical patent/MX381651B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica para administración tópica que comprende un compuesto de fórmula I, ácido 3-{4-[2-{5-cloro-1-(difenilmetil)-2-[2-({[2-(trifluoromet il)bencil]sulfonil}amino)etil]-1H-indol-3-il}etil]sulfonil}fenil} propanoico o sales farmacéuticamente aceptables del mismo; y a métodos para tratar inflamación que comprenden la administración tópica de una composición que comprende un compuesto de fórmula I.
MX2016010083A 2014-02-04 2015-02-04 Composicion farmaceutica para administracion topica. MX381651B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB201401904A GB201401904D0 (en) 2014-02-04 2014-02-04 Pharmaceutical composition for topical administration
PCT/GB2015/050299 WO2015118320A1 (en) 2014-02-04 2015-02-04 Pharmaceutical composition for topical administration

Publications (2)

Publication Number Publication Date
MX2016010083A true MX2016010083A (es) 2017-02-02
MX381651B MX381651B (es) 2025-03-11

Family

ID=50344377

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016010083A MX381651B (es) 2014-02-04 2015-02-04 Composicion farmaceutica para administracion topica.
MX2020013311A MX2020013311A (es) 2014-02-04 2016-08-03 Composicion farmaceutica para administracion topica.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020013311A MX2020013311A (es) 2014-02-04 2016-08-03 Composicion farmaceutica para administracion topica.

Country Status (15)

Country Link
US (2) US9693995B2 (es)
EP (1) EP3102201A1 (es)
JP (2) JP6523311B2 (es)
KR (1) KR102415152B1 (es)
CN (1) CN106456607B (es)
AU (1) AU2015213878B2 (es)
BR (2) BR122019021030B1 (es)
CA (1) CA2938728A1 (es)
GB (1) GB201401904D0 (es)
HK (1) HK1231390A1 (es)
IL (1) IL246930B (es)
MX (2) MX381651B (es)
RU (1) RU2703557C1 (es)
WO (1) WO2015118320A1 (es)
ZA (1) ZA201605263B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201401904D0 (en) 2014-02-04 2014-03-19 Ziarco Pharma Ltd Pharmaceutical composition for topical administration
AU2018390563B2 (en) * 2017-12-19 2024-07-04 University Of Tennessee Research Foundation W/o/w microemulsions for ocular administration
CN108676770A (zh) * 2018-05-24 2018-10-19 北京熙朵医疗美容门诊部有限公司 用于cht活细胞植发技术的毛囊活化液及其制备方法
CN114340597B (zh) * 2019-06-07 2025-01-28 帕克斯医学有限公司 用于治疗中枢神经系统障碍的组合物和方法
JP2023540665A (ja) * 2020-06-30 2023-09-26 デルミラ インコーポレイテッド ＲＯＲγＴ阻害剤及びそれらの局所使用
CN113893220A (zh) * 2020-07-07 2022-01-07 迈德欣国际有限公司 鼻粘膜给药剂型和其应用
KR20230129639A (ko) * 2022-03-02 2023-09-11 연세대학교 산학협력단 이중작용 pde5 억제제/질산유기에스터의 국소 혈류 증진을 위한 경피 투약 형태
CN116983312B (zh) * 2023-05-24 2024-07-05 凌科药业(杭州)有限公司 一种药物组合物、外用制剂及其制备方法、应用
CN116832033A (zh) * 2023-07-14 2023-10-03 新疆医科大学第三附属医院 Cay10650在制备治疗肝癌和脂肪肝的药物中的应用
US12514756B1 (en) 2024-10-08 2026-01-06 Covidien Lp Dermal patch and systems, kits, and methods associated therewith

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2225208C1 (ru) * 2002-10-17 2004-03-10 Открытое акционерное общество "Химико-фармацевтический комбинат "Акрихин" Фармацевтическая композиция, обладающая противовоспалительным и антиаллергическим действием
FR2851470B1 (fr) * 2003-02-20 2007-11-16 Besins Int Belgique Composition pharmaceutique pour administration transdermique ou transmuqueuse
TW200718687A (en) * 2005-05-27 2007-05-16 Wyeth Corp Inhibitors of cytosolic phospholipase A2
BRPI0718042A2 (pt) * 2006-10-31 2013-11-12 Wyeth Corp Formulações semissólidas de inibidores de enzima fosfolipase
EP2104498A2 (en) 2006-10-31 2009-09-30 Wyeth Liquid formulations of phospholipase enzyme inhibitors
EP2468270A1 (en) 2010-12-21 2012-06-27 GALENpharma GmbH (R)-2-(3-fluoro-4-phenylphenyl)propionic acid for use in the treatment of skin diseases
GB201401904D0 (en) 2014-02-04 2014-03-19 Ziarco Pharma Ltd Pharmaceutical composition for topical administration

Also Published As

Publication number Publication date
CA2938728A1 (en) 2015-08-13
ZA201605263B (en) 2022-09-28
AU2015213878B2 (en) 2020-05-07
US20170007576A1 (en) 2017-01-12
MX2020013311A (es) 2021-02-22
IL246930A0 (en) 2016-09-29
JP2019151645A (ja) 2019-09-12
US20170273945A1 (en) 2017-09-28
MX381651B (es) 2025-03-11
JP7094243B2 (ja) 2022-07-01
KR102415152B1 (ko) 2022-06-29
US9693995B2 (en) 2017-07-04
WO2015118320A1 (en) 2015-08-13
JP2017505320A (ja) 2017-02-16
CN106456607A (zh) 2017-02-22
AU2015213878A1 (en) 2016-08-11
CN106456607B (zh) 2021-08-27
KR20160127014A (ko) 2016-11-02
BR112016017985B1 (pt) 2019-12-31
IL246930B (en) 2020-10-29
EP3102201A1 (en) 2016-12-14
BR122019021030B1 (pt) 2021-11-30
US10034858B2 (en) 2018-07-31
JP6523311B2 (ja) 2019-05-29
HK1231390A1 (zh) 2017-12-22
NZ722505A (en) 2021-04-30
BR112016017985A2 (pt) 2017-08-08
RU2703557C1 (ru) 2019-10-21
GB201401904D0 (en) 2014-03-19

Similar Documents

Publication Publication Date Title
MX2016010083A (es) Composicion farmaceutica para administracion topica.
CY1124848T1 (el) Φαρμακευτικες συνθεσεις που περιλαμβανουν azd9291
CL2023001369A1 (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CL2016001458A1 (es) Derivado de sulfonamida o sales de adición de ácido farmaceuticamente aceptables del mismo.
PH12017500914A1 (en) Bile acid analogs as fxr/tgr5 agonists and methods of use thereof
UY35998A (es) 1-(3-(tert-BUTIL)1-(p-TOLIL)-1H-PIRAZOL-5-IL)-3-(4-((2-((6-ETILPIRAZIN-2-IL)AMINO)PIRIDIN-4-IL)METOXI)NAFTALEN-1-IL) UREA Y SUS SALES DERIVADAS FARMACÉUTICAMENTE ACEPTABLES, COMO INHIBIDORES DE P38 M AP QUINASA
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
MX2017006832A (es) Derivados de ácido biliar como agonistas de fxr/tgr5 y métodos para el uso de los mismos.
EA201492281A1 (ru) Соединения n-арилтриазола в качестве антагонистов рецепторов лизофосфатидной кислоты (lpar)
CO7160104A2 (es) Inhibidores de virus de hepatitis c
CL2018000811A1 (es) Formulaciones de aminoácidos de liberación modificada administradas por vía oral.
UY33885A (es) Inhibición de la il17 y del ifn-gamma para el tratamiento de las inflamaciones autoinmunes
ECSP14007965A (es) Formulaciones de (+)-2-[1-(3-etoxi-4-metoxi-fenil)-2-metansulfonil-etil]-4-acetil aminoisoindolin-1, 3-diona
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
AR103680A1 (es) Inhibidores selectivos de bace1
EA201690741A1 (ru) Составы (s)-3-(4-((4-(морфолинометил)бензил)окси)-1-оксоизоиндолин-2-ил)пиперидин-2,6-диона
MX2016009049A (es) Composicion farmaceutica que contiene compuesto de acido piridilaminoacetico.
EA201691600A1 (ru) Дигидропиридиноновые ингибиторы mgat2 для применения в лечении метаболических нарушений
AR094921A1 (es) Derivados de 2-acilaminotiazol o su sal
AR090592A1 (es) Sales de 5-[(1r)-2-({2-[4-(2,2-difluoro-2-feniletoxi)fenil]etil}amino)-1-hidroxietil]-8-hidroxiquinolin-2(1h)-ona
EA201692298A1 (ru) Производные карбоксамидов
CY1122598T1 (el) Οφθαλμικη φαρμακευτικη συνθεση περιεχουσα αναστολεα καρβονικης ανυδρασης και μεθοδος για την παρασκευη αυτης
PE20181019A1 (es) Monohidrato de (s)-lactato de 5-(5-(2-(3-aminopropoxi)-6-metoxifenil)-1h-pirazol-3-ilamino)pirazin-2-carbonitrilo
EA201300281A2 (ru) Новый способ синтеза ивабрадина и его аддитивных солей с фармацевтически приемлемой кислотой
EA202091668A3 (ru) Ингибиторы калликреина плазмы человека